EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS) finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Study results
Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia.
EQS-News: Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): StudyNewron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide 29.12.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Newron completes enrollment of schizophrenia patie.